Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Rizk DV, Silva AL, Pergola PE, Toto R, Warnock DG, Chin MP, Goldsberry A, O'Grady M, Meyer CJ, McCullough PA.

Cardiorenal Med. 2019 Jun 6:1-10. doi: 10.1159/000500612. [Epub ahead of print]

2.

Dietary Oxidative Balance Scores and Biomarkers of Inflammation among Individuals with and without Chronic Kidney Disease.

Marks KJ, Hartman TJ, Judd SE, Ilori TO, Cheung KL, Warnock DG, Gutiérrez OM, Goodman M, Cushman M, McClellan WM.

Nephron Extra. 2018 Aug 21;8(2):11-23. doi: 10.1159/000490499. eCollection 2018 May-Aug.

3.

Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study.

Dubin RF, Judd S, Scherzer R, Shlipak M, Warnock DG, Cushman M, Sarnak M, Parikh C, Bennett M, Powe N, Peralta CA.

Kidney Int Rep. 2018 Jun 20;3(5):1183-1192. doi: 10.1016/j.ekir.2018.05.013. eCollection 2018 Sep.

4.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG.

J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1.

5.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

6.

Serum albumin concentration and risk of end-stage renal disease: the REGARDS study.

Walther CP, Gutiérrez OM, Cushman M, Judd SE, Lang J, McClellan W, Muntner P, Sarnak MJ, Shlipak MG, Warnock DG, Katz R, Ix JH.

Nephrol Dial Transplant. 2018 Oct 1;33(10):1770-1777. doi: 10.1093/ndt/gfx331.

PMID:
29281114
7.

Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery.

Swaminathan M, Stafford-Smith M, Chertow GM, Warnock DG, Paragamian V, Brenner RM, Lellouche F, Fox-Robichaud A, Atta MG, Melby S, Mehta RL, Wald R, Verma S, Mazer CD; ACT-AKI investigators.

J Am Soc Nephrol. 2018 Jan;29(1):260-267. doi: 10.1681/ASN.2016101150. Epub 2017 Oct 16.

8.

Conjunctival lymphangiectasia associated with classic Fabry disease.

Sivley MD, Wallace EL, Warnock DG, Benjamin WJ.

Br J Ophthalmol. 2018 Jan;102(1):54-58. doi: 10.1136/bjophthalmol-2016-310088. Epub 2017 May 12.

PMID:
28500230
9.

Evaluation of Renal Function and Renal Risk in the Twenty-First Century.

Porrini E, Warnock DG.

Nephron. 2017;136(4):261-262. doi: 10.1159/000471757. Epub 2017 May 6. No abstract available.

10.

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.

Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209.

PMID:
28431138
11.

Global Cardiovascular and Renal Outcomes of Reduced GFR.

Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barregård L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schöttker B, Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi M, Forouzanfar MH, Murray CJL, Coresh J, Vos T; Global Burden of Disease 2013 GFR Collaborators; CKD Prognosis Consortium; Global Burden of Disease Genitourinary Expert Group.

J Am Soc Nephrol. 2017 Jul;28(7):2167-2179. doi: 10.1681/ASN.2016050562. Epub 2017 Apr 13.

12.

The Fault Is Not in Our Stars but May Be in Our Embryos: Glomerular Number in Low Birth Weight Babies.

Warnock DG.

Nephron. 2017;136(1):1-2. doi: 10.1159/000465509. Epub 2017 Mar 23. No abstract available.

13.

Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria.

Warnock DG, Delanaye P, Glassock RJ.

Nephron. 2017;136(4):292-297. doi: 10.1159/000455197. Epub 2017 Jan 27. Review.

14.

Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C; Conference Participants.

Kidney Int. 2017 Feb;91(2):284-293. doi: 10.1016/j.kint.2016.10.004. Epub 2016 Dec 18.

15.

The global burden of chronic kidney disease: estimates, variability and pitfalls.

Glassock RJ, Warnock DG, Delanaye P.

Nat Rev Nephrol. 2017 Feb;13(2):104-114. doi: 10.1038/nrneph.2016.163. Epub 2016 Dec 12. Review.

16.

Serum Creatinine Trajectories for Community- versus Hospital-Acquired Acute Kidney Injury.

Warnock DG, Powell TC, Siew ED, Donnelly JP, Wang HE, Mehta RL.

Nephron. 2016;134(3):177-182. Epub 2016 Jul 26.

17.

Epilogue: UAB Symposium November 2015.

Warnock DG.

Nephron. 2016;134(1):50. doi: 10.1159/000449144. Epub 2016 Aug 27. No abstract available.

18.

Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.

Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR.

Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13.

19.

The pressing need for real-time risk assessment of hospital-acquired acute kidney injury.

Warnock DG.

Nephrol Dial Transplant. 2017 May 1;32(5):766-770. doi: 10.1093/ndt/gfw282. Review.

PMID:
27461745
20.

Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults.

Panwar B, Judd SE, Warnock DG, McClellan WM, Booth JN 3rd, Muntner P, Gutiérrez OM.

Stroke. 2016 Aug;47(8):2017-24. doi: 10.1161/STROKEAHA.116.013077. Epub 2016 Jul 5.

21.

Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.

Ito S, Ogura M, Kamei K, Matsuoka K, Warnock DG.

Pediatr Nephrol. 2016 Aug;31(8):1369-73. doi: 10.1007/s00467-016-3387-4. Epub 2016 Apr 29.

PMID:
27129690
22.

Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults.

Bowling CB, Bromfield SG, Colantonio LD, Gutiérrez OM, Shimbo D, Reynolds K, Wright NC, Curtis JR, Judd SE, Franch H, Warnock DG, McClellan W, Muntner P.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1236-43. doi: 10.2215/CJN.11111015. Epub 2016 Apr 18.

23.

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.

Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG.

J Med Genet. 2016 Jul;53(7):495-502. doi: 10.1136/jmedgenet-2015-103486. Epub 2016 Mar 18.

24.

The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old.

Colantonio LD, Tanner RM, Warnock DG, Gutiérrez OM, Judd S, Muntner P, Bowling CB.

Arch Med Sci. 2016 Feb 1;12(1):55-67. doi: 10.5114/aoms.2016.57580. Epub 2016 Feb 2.

25.

Competing risks: you only die once.

Warnock DG.

Nephrol Dial Transplant. 2016 Jul;31(7):1033-5. doi: 10.1093/ndt/gfv455. Epub 2016 Jan 31. No abstract available.

26.

Estimated Glomerular Filtration Rate: Fit for What Purpose?

Warnock DG.

Nephron. 2016;134(1):43-9. doi: 10.1159/000444062. Epub 2016 Feb 5. Review.

27.

Validation of an Albuminuria Self-assessment Tool in the Multi-Ethnic Study of Atherosclerosis.

Tanner RM, Woodward M, Peralta C, Warnock DG, Gutiérrez O, Shimbo D, Kramer H, Katz R, Muntner P.

Ethn Dis. 2015 Nov 5;25(4):427-34. doi: 10.18865/ed.25.4.427.

28.

Past Decline Versus Current eGFR and Subsequent Mortality Risk.

Naimark DM, Grams ME, Matsushita K, Black C, Drion I, Fox CS, Inker LA, Ishani A, Jee SH, Kitamura A, Lea JP, Nally J, Peralta CA, Rothenbacher D, Ryu S, Tonelli M, Yatsuya H, Coresh J, Gansevoort RT, Warnock DG, Woodward M, de Jong PE; CKD Prognosis Consortium.

J Am Soc Nephrol. 2016 Aug;27(8):2456-66. doi: 10.1681/ASN.2015060688. Epub 2015 Dec 11.

29.

Categories of Hospital-Associated Acute Kidney Injury: Time Course of Changes in Serum Creatinine Values.

Warnock DG, Powell TC, Donnelly JP, Wang HE.

Nephron. 2015;131(4):227-36. doi: 10.1159/000441956. Epub 2015 Nov 17.

30.

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, Jackson LL, Wilcox WR, Wanner C.

J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21.

31.

Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Amador CA, Bertocchio JP, Andre-Gregoire G, Placier S, Duong Van Huyen JP, El Moghrabi S, Berger S, Warnock DG, Chatziantoniou C, Jaffe IZ, Rieu P, Jaisser F.

Kidney Int. 2016 Feb;89(2):354-62.

32.

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.

Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F.

J Am Soc Nephrol. 2016 Feb;27(2):398-404. doi: 10.1681/ASN.2014121216. Epub 2015 Sep 11.

33.

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

Warnock DG, Bichet DG, Holida M, Goker-Alpan O, Nicholls K, Thomas M, Eyskens F, Shankar S, Adera M, Sitaraman S, Khanna R, Flanagan JJ, Wustman BA, Barth J, Barlow C, Valenzano KJ, Lockhart DJ, Boudes P, Johnson FK.

PLoS One. 2015 Aug 7;10(8):e0134341. doi: 10.1371/journal.pone.0134341. eCollection 2015.

34.

Appendiceal tissue confirmation of Fabry's disease.

Wallace EL, Fatima H, Jackson LJ, Warnock DG.

Kidney Int. 2015 Aug;88(2):417. doi: 10.1038/ki.2014.399. No abstract available.

PMID:
26230208
35.

Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.

Kramer H, Gutiérrez OM, Judd SE, Muntner P, Warnock DG, Tanner RM, Panwar B, Shoham DA, McClellan W.

Am J Kidney Dis. 2016 Jan;67(1):62-9. doi: 10.1053/j.ajkd.2015.05.023. Epub 2015 Jul 15.

36.

Amiloride: the "new" renal tonic?

Warnock DG.

Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F429-30. doi: 10.1152/ajprenal.00237.2015. Epub 2015 Jun 17. No abstract available.

37.

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.

Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, Kobayashi Y, Abiko H, Satou M, Nakahata T, Warnock DG, Sakuraba H, Shibasaki F.

PLoS One. 2015 Jun 17;10(6):e0128351. doi: 10.1371/journal.pone.0128351. eCollection 2015.

38.

Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium.

Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25. doi: 10.1016/S2213-8587(15)00040-6. Epub 2015 May 28.

39.

A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury.

James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ; CKD Prognosis Consortium.

Am J Kidney Dis. 2015 Oct;66(4):602-12. doi: 10.1053/j.ajkd.2015.02.338. Epub 2015 May 11. Review.

40.

Oral anticoagulants and risk of nephropathy.

Narasimha Krishna V, Warnock DG, Saxena N, Rizk DV.

Drug Saf. 2015 Jun;38(6):527-33. doi: 10.1007/s40264-015-0290-z. Review.

PMID:
25913726
41.

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.

Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR.

J Med Genet. 2015 May;52(5):353-8. doi: 10.1136/jmedgenet-2014-102797. Epub 2015 Mar 20.

42.

The Furosemide Stress Test and Predicting AKI Outcomes.

Powell TC, Warnock DG.

J Am Soc Nephrol. 2015 Aug;26(8):1762-4. doi: 10.1681/ASN.2014121160. Epub 2015 Feb 5. No abstract available.

43.

Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessments.

Wadley VG, McClure LA, Warnock DG, Lassen-Greene CL, Hopkin RJ, Laney DA, Clarke VM, Kurella Tamura M, Howard G, Sims K.

JIMD Rep. 2015;18:41-50. doi: 10.1007/8904_2014_346. Epub 2015 Jan 8.

44.

Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.

Tøndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E.

Nephron. 2015;129(1):16-21. doi: 10.1159/000369309. Epub 2014 Dec 17.

45.

Obesity, metabolic health, and the risk of end-stage renal disease.

Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, Warnock DG, Judd SE, Gutiérrez OM.

Kidney Int. 2015 Jun;87(6):1216-22. doi: 10.1038/ki.2014.384. Epub 2014 Dec 17.

46.

Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.

Judd EK, Calhoun DA, Warnock DG.

Semin Nephrol. 2014;34(5):532-9. doi: 10.1016/j.semnephrol.2014.08.007. Review.

47.

Contrasting Cholesterol Management Guidelines for Adults with CKD.

Colantonio LD, Baber U, Banach M, Tanner RM, Warnock DG, Gutiérrez OM, Safford MM, Wanner C, Howard G, Muntner P.

J Am Soc Nephrol. 2015 May;26(5):1173-80. doi: 10.1681/ASN.2014040400. Epub 2014 Nov 13.

48.

Nondisease-specific problems and all-cause mortality among older adults with CKD: the REGARDS Study.

Bowling CB, Booth JN 3rd, Gutiérrez OM, Kurella Tamura M, Huang L, Kilgore M, Judd S, Warnock DG, McClellan WM, Allman RM, Muntner P.

Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1737-45. doi: 10.2215/CJN.00880114. Epub 2014 Oct 2.

49.

Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Muntner P, Gutiérrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB.

Am J Kidney Dis. 2015 Feb;65(2):249-58. doi: 10.1053/j.ajkd.2014.07.012. Epub 2014 Sep 19.

50.

Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.

Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JT, Bichet DG, Warnock DG, Echevarria L, West ML, Lavoie P.

Clin Chim Acta. 2015 Jan 1;438:195-204. doi: 10.1016/j.cca.2014.08.002. Epub 2014 Aug 19.

PMID:
25149322

Supplemental Content

Loading ...
Support Center